1
项与 Circumsporozoite vaccine (fowlpox virus vector, malaria), London School of Hygiene and Tropical Medicine(University of Oxford) 相关的临床试验A Phase 1 Trial of the Malaria Candidate Vaccines FP9 CS and MVA CS in Adult Gambian Men Aged 18 - 45 Years
Animal and human studies have shown that the prime-boost immunization strategy using malaria antigens expressed in plasmid or viral vectors induces strong cellular immune responses. An immunization regimen with the malaria vaccines DNA ME-TRAP followed by MVA ME-TRAP induced strong T cell responses in adults in the United Kingdom (UK) and in the Gambia but did not provide significant clinical protection against infection. The investigators assessed two new vaccines which utilize a similar immunization strategy but a different malaria antigen, a circumsporozoite (CS) protein. The entire CS protein was expressed either in a modified vaccinia virus Ankara (MVA) CS, or an attenuated fowlpox virus strain (FP9) CS.
100 项与 Circumsporozoite vaccine (fowlpox virus vector, malaria), London School of Hygiene and Tropical Medicine(University of Oxford) 相关的临床结果
100 项与 Circumsporozoite vaccine (fowlpox virus vector, malaria), London School of Hygiene and Tropical Medicine(University of Oxford) 相关的转化医学
100 项与 Circumsporozoite vaccine (fowlpox virus vector, malaria), London School of Hygiene and Tropical Medicine(University of Oxford) 相关的专利(医药)
100 项与 Circumsporozoite vaccine (fowlpox virus vector, malaria), London School of Hygiene and Tropical Medicine(University of Oxford) 相关的药物交易